Compare SMX & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMX | MREO |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Ireland | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.8M | 324.6M |
| IPO Year | N/A | N/A |
| Metric | SMX | MREO |
|---|---|---|
| Price | $140.66 | $2.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 3.8M | 2.2M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $131.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.12 | $1.47 |
| 52 Week High | $66,187.38 | $3.90 |
| Indicator | SMX | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 56.14 | 62.28 |
| Support Level | $96.01 | $2.02 |
| Resistance Level | $272.00 | $2.37 |
| Average True Range (ATR) | 67.82 | 0.15 |
| MACD | 8.03 | 0.04 |
| Stochastic Oscillator | 28.48 | 69.05 |
SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).